Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
41.51
+1.54 (3.85%)
Oct 29, 2026, 2:18 PM EDT - Market open
Teva Pharmaceutical Financials Overview
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 17,315 | 17,258 | 16,544 | 15,846 | 14,925 | 15,878 |
Revenue Growth | 4.13% | 4.32% | 4.41% | 6.17% | -6.00% | -4.69% |
Gross Profit Gross Profit Growth | 9,083 | 8,938 | 8,063 | 7,646 | 6,973 | 7,594 |
Operating Income Operating Income Growth | 3,280 | 3,952 | 3,373 | 3,185 | 2,662 | 3,079 |
Net Income Net Income Growth | 706 | 1,410 | -1,639 | -559 | -2,446 | 417 |
Earnings Per Share EPS Growth | 0.60 | 1.21 | -1.45 | -0.50 | -2.20 | 0.38 |
EPS Growth | - | - | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue from Sale of Goods Revenue from Sale of Goods Growth | 14,566 | 14,605 | 14,050 | 12,979 | 12,766 | 13,829 |
Licensing Arrangements Licensing Arrangements Growth | 672 | 678 | 173 | 681 | 212 | 160 |
Distribution Distribution Growth | 1,619 | 1,551 | 1,576 | 1,615 | 1,519 | 1,390 |
Other Segment Other Segment Growth | 457 | 423 | 745 | 570 | 428 | 500 |
Revenue (Total) Revenue (Total) Growth | 17,315 | 17,258 | 16,544 | 15,846 | 14,925 | 15,878 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 3,655 | 3,556 | 3,300 | 3,226 | 2,801 | 2,165 |
Total Debt Total Debt Growth | 16,894 | 17,230 | 18,184 | 20,273 | 21,676 | 23,593 |
Net Cash (Debt) Net Cash Growth | -13,239 | -13,674 | -14,884 | -17,047 | -18,875 | -21,428 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -11.38 | -11.76 | -13.16 | -15.23 | -17.00 | -19.36 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 1,898 | 1,649 | 1,247 | 1,368 | 1,590 | 798 |
Capital Expenditures CapEx Growth | -551 | -501 | -498 | -526 | -548 | -562 |
Free Cash Flow Free Cash Flow Growth | 1,347 | 1,148 | 749 | 842 | 1,042 | 236 |
Free Cash Flow Growth | 51.35% | 53.27% | -11.04% | -19.19% | 341.52% | -63.01% |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 52.46% | 51.79% | 48.74% | 48.25% | 46.72% | 47.83% |
Operating Margin | 18.94% | 22.90% | 20.39% | 20.10% | 17.84% | 19.39% |
Pretax Margin | 4.15% | 7.17% | -7.76% | -3.93% | -21.05% | 4.20% |
Profit Margin | 4.08% | 8.17% | -9.91% | -3.53% | -16.39% | 2.63% |
FCF Margin | 7.78% | 6.65% | 4.53% | 5.31% | 6.98% | 1.49% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Oct '26 Oct 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 68.99 | 23.28 | - | - | - | 22.88 |
P/FCF Ratio | 35.13 | 28.59 | 28.02 | 11.48 | 9.53 | 40.43 |
PS Ratio | 2.73 | 1.90 | 1.27 | 0.61 | 0.67 | 0.60 |